Case Study: EEG Digital Biomarkers in Neuropsychiatric Clinical Studies

Description

Discover an informative webinar discussing digital biomarkers in neuropsychiatric trials, leveraging an artificial intelligence (AI)-driven platform for enhanced treatment outcomes. Drugs for psychiatric conditions suffer some of the lowest approval rates when compared to other major therapeutic areas. Underlying factors can include complex and poorly understood etiology, which are heterogeneous in presentation, and underlying pathophysiology. Additionally, traditional clinical studies fail to objectively assess cognitive function as part of patient eligibility criteria or stratify patients according to the presence or degree of cognitive impairment. Cognitive function assessments and electroencephalogram (EEG) enable the measurement of pharmacodynamic endpoints in early-stage, translational psychiatric studies, however many studies do not leverage these tools today.